Human Milk Oligosaccharides (HMOs): Structure, Function, and Research Applications

Human milk oligosaccharides (HMOs) are a diverse family of complex carbohydrates found almost exclusively in human breast milk. With concentrations of 5–15 g/L in mature milk and up to 20–25 g/L in colostrum, HMOs are the third most abundant solid after lactose and fat. Despite their abundance, infants cannot digest HMOs — they serve as functional bioactive agents rather than caloric substrates.

Structural Diversity of HMOs

More than 200 structurally distinct HMOs have been identified, all built on a common lactose (Galβ1-4Glc) core. Elongation occurs via alternating β1-3 and β1-6 glycosidic linkages using lacto-N-biose or N-acetyllactosamine units. The resulting chains can be further decorated with fucose (α1-2 or α1-3/4 linkages) and/or sialic acid (α2-3 or α2-6 linkages). The diversity arises from combinatorial assembly of these building blocks.

• 2'-Fucosyllactose (2'-FL) — the most abundant HMO in most mothers' milk; α1-2-fucosylated lacose. Present in infant formula supplementation trials.
• Lacto-N-tetraose (LNT) — a core type-1 chain structure; benchmark for lactose-extended HMOs.
• Lacto-N-neotetraose (LNnT) — type-2 chain counterpart of LNT; both are approved for infant formula use in several jurisdictions.
• 3'-Sialyllactose (3'-SL) and 6'-Sialyllactose (6'-SL) — sialylated core HMOs; major precursors of ganglioside-type structures.
• Difucosyllactose (DFL / LNDFH) — highly fucosylated structures with potent anti-adhesion activity against bacterial pathogens.

Biological Functions

Prebiotic Activity and Microbiome Shaping

The primary biological role attributed to HMOs is selective modulation of the infant gut microbiome. Bifidobacterium longum subsp. infantis and related strains encode HMO-specific transporters and glycoside hydrolases that allow them to consume HMOs as a primary carbon source. This confers a competitive advantage over non-HMO-consuming bacteria, promoting the bloom of Bifidobacterium that characterizes the breastfed infant gut.

Pathogen Decoys

Many enteric pathogens — including Campylobacter jejuni, enteropathogenic E. coli, and Vibrio cholerae — use glycan structures as adhesion receptors on epithelial cells. HMOs that mimic these glycan structures can act as soluble decoys, competitively inhibiting pathogen binding. 2'-FL, for instance, bears structural similarity to H-antigen Lewis blood group epitopes and has been shown to reduce adhesion of Campylobacter to intestinal cells in vitro.

Immune Modulation and Intestinal Maturation

HMOs directly interact with intestinal epithelial cells and immune cells. Several studies have demonstrated that HMOs reduce NF-κB activation and pro-inflammatory cytokine production in intestinal epithelial models. They also appear to accelerate intestinal barrier maturation, increasing tight junction protein expression. These effects may contribute to the lower incidence of necrotizing enterocolitis (NEC) observed in breastfed premature infants.

Neurological Development

Sialylated HMOs (3'-SL and 6'-SL) are potential precursors for brain ganglioside synthesis. During the rapid brain growth of the first year of life, the demand for sialic acid is exceptionally high. Several animal studies suggest that HMO-supplemented diets improve cognitive outcomes compared with unsupplemented controls, though direct evidence in human infants remains an active area of investigation.

Research Applications of HMOs

• Microbiome studies — use individual HMOs to selectively stimulate or inhibit bacterial strains in vitro and in germ-free mouse models.
• Lectin and pathogen adhesion assays — coat microplates or glycan arrays with defined HMOs to screen adhesins and lectins.
• Enzyme characterization — HMOs are excellent substrates for characterizing novel glycosidases from gut microbiota.
• Infant formula development — regulatory-approved HMOs (2'-FL, LNnT, 3'-SL, etc.) for supplementation studies.
• Mass spectrometry method development — the structural diversity of HMOs makes them valuable standards for developing glycan LC-MS/MS methods.